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The aim of this study was to investigate whether high glucose induces aldose reductase (AKR1B1) expression through NFκB, which may
contribute to the pathogenesis of diabetic nephropathy. 34 Caucasoid patients with type 1 diabetes were recruited; 20 nephropaths and 14 long-
term uncomplicated subjects. Peripheral blood mononuclear cells (PBMCs) were cultured under normal or high glucose (25 mmol/l of D-glucose)
with or without an aldose reductase inhibitor (ARI). High glucose increased NFκB binding activities in the PBMCs from nephropaths compared to
the uncomplicated subjects (1.77±0.22 vs. 1.16±0.04, p=0.02). ARI induced a substantially greater decrease of NFκB binding activities in the
nephropaths compared to the uncomplicated subjects (0.58±0.06 vs. 0.79±0.06, p=0.032). AKR1B1 protein levels in the nephropaths were
increased under high glucose conditions and decreased in the presence of an ARI, whilst the silencing of the NFκB p65 gene in vitro reduced the
transcriptional activities of AKR1B1 in luciferase assays. These results show that NFκB induces AKR1B1expression under high glucose
conditions, and the pattern of expression differs between nephropaths and the uncomplicated subjects.
© 2008 Elsevier B.V. All rights reserved.Keywords: Nuclear factor kappa B; Diabetic nephropathy; Aldose reductase; Aldose reductase inhibitor; siRNA1. Introduction
A large number of patients with type 1 and type 2 diabetes
mellitus will develop one or more chronic microvascular com-
plications during the course of their diabetes. The precise
mechanisms that initiate and promote diabetic microvascular
complications are still being elucidated. It is well established
that high glucose stimulates increased flux through the polyol
pathway, and this is linked to abnormalities such as osmotic and
oxidative stresses that have been cited as promoters of diabetic
microvascular disease [1–3].
Aldose reductase (AKR1B1) is the first and rate-limiting
enzyme of the polyol pathway and its expression is tightly
regulated by intracellular osmolality at the transcriptional level⁎ Corresponding author. Molecular Medicine Research Group, Institute of
Biomedical and Clinical Science, Peninsula Medical School, Tamar Science
Park, Plymouth PL6 8BU, UK. Tel.: +44 1752 437410; fax: +44 1752 517846.
E-mail address: andy.demaine@pms.ac.uk (A.G. Demaine).
0925-4439/$ - see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2008.01.009[4]. This is mediated through the osmotic response elements
(OREs) located in the 5′ flanking sequences of the AKR1B1
gene [5]. There are three OREs, (OREA, OREB and OREC),
that act as specific binding sites for the transcription factor,
nuclear factor of activated T cells 5 (NFAT5) or the TonE
binding protein (TonEBP) [5]. Our previous study has
demonstrated that high glucose significantly increased the
DNA-binding activity of NFAT5 to the OREs, in particular to
the OREC [6]. Furthermore, this increase was significantly
higher in patients with type 1 diabetes and nephropathy
compared with those patients without microvascular complica-
tions. These results indicate that AKR1B1 is up-regulated by
the transcriptional factor NFAT5 under high glucose
conditions.
Nuclear factor kappa B (NFκB) is a redox-sensitive tran-
scriptional factor which shares the binding site with OREC in
the promoter region of AKR1B1 gene with NFAT5 [7]. NFκB
is a widely expressed and is an inducible transcriptional factor
with an inactive cytoplasmic and active nuclear DNA-binding
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through a rapid phosphorylation of IκB-α, which is
dissociated from NFκB and is rapidly translocated to the
nucleus where it binds to a κB site and activates its target
genes. High glucose-increased flux through the polyol
pathway induces redox change and oxidative stress, which
activates NFκB. As a result, increased NFκB activity may
induce the expression of AKR1B1 by binding to the κB motif
in the promoter region of AKR1B1 gene under high glucose
conditions. At the same time, NFκB binds to other target
genes to increase transcription of these genes, such as
macrophage chemotactic protein (MCP-1) and metallo-
matrix-proteinases (MMPs) which are involved in the
accumulation of extracellular matrix and contributes to the
development of diabetic complications [8–10]. Increased
activity of NFκB in patients with type 1 as well as type 2
diabetes with microvascular complications has been observed
by several groups [11–14]. Ramana et al. [15] demonstrated
that inhibition of AKR1B1 prevented hyperglycemia-induced
NFκB activation in vascular smooth muscle cells. They ob-
served that aldose reductase inhibitors (ARI) inhibited the
translocation of NFκB and decreased NFκB DNA-binding
activities.
The aims of the present study were to determine whether the
AKR1B1 gene expression is regulated by NFκB under high
glucose conditions, and whether this expression is different
between those patients with or without nephropathy. Finally, we
investigated the effects of ARI on the NFκB binding, and the
effects of the silencing of the NFκB p65 subunit on the ex-
pression of AKR1B1 gene in vitro.
2. Materials and methods
2.1. SubjectsThe following Caucasoid subjects were included in this study: 34 patients
with type 1 diabetes. All patients with type 1 as defined by The Expert Com-
mittee on The Diagnosis and Classification of Diabetes Mellitus [16] had
attended the Diabetes Clinic, Derriford Hospital, Plymouth. The study was ap-
proved by the Local Research Ethical Committee and informed consent was
obtained from all subjects. The criteria for diabetic microvascular complications
have been published previously [17].
Uncomplicated subjects (Uncompls: n=14) have been diagnosed with type
1 for at least 20 years but remain free of retinopathy (fewer than five dots or blots
per fundus), proteinuria (urine Albustix negative on at least three consecutive
occasions over 12 months) and neuropathy (overt neuropathy was defined if
there was any clinical evidence of peripheral or autonomic neuropathy).
Diabetic nephropaths (Nephropaths: n=20) have had type 1 for at least
8 years with persistent proteinuria (urine Albustix positive on at least three
consecutive occasions over 12 months or three consecutive total urinary protein
excretion rates N0.5 g/24 h) in the absence of hematuria or infection on mid-
stream urine samples. Diabetic nephropathy was always associated with retino-
pathy. Retinopathy was defined as more than five dots or blots per eye; hard or
soft exudates, new vessels, or fluorescein angiographic evidence of maculopathy
or previous laser treatment for pre-proliferative or proliferative retinopathy; and
maculopathy or vitreous haemorrhage. Fundoscope was performed by both a
diabetologist and an ophthalmologist.
2.1.1. Cell isolation and cultures
Peripheral venous blood samples (20 ml) were collected into 5% EDTA
Vacutainers (Becton Dickinson, UK). The PBMCs were separated by usingHistopaque (Sigma, Dorset, UK) and grown in RPMI 1640 supplemented with
D-glucose at a 5.5 mmol/l of concentration, 10% calf serum and 2 mmol/l
L-glutamine, 100 units/ml penicillin G sodium and 100 mg/ml streptomycin
sulphate with PHA-P at 5 μg/ml of concentration in a 37 °C incubator with a
controlled, humidified atmosphere of 95% air/5% CO2. These cells were
divided into three groups from each individual in 200 ml-flasks. Group 1 (NG):
cells were cultured in the above medium. Group 2 (HG): 19.5 mmol/l extra D-
glucose was added into the above-mentioned medium. Group 3 (ARI+HG):
sorbinil (10 µmol/l) which is an ARI was added into the above-mentioned
medium and 3 h later 19.5 mmol/l extra D-glucose was added to the culture
medium [15]. All cells were incubated for 5 days. At the end of the incubation
time, cells were harvested and nuclear and cytoplasmic proteins were extracted
from PBMC as below. A portion of the PBMCs in some samples were cultured
with mannitol for 5 days (a final concentration at 25 mM) as positive controls.
HEK 293 were cultured in EMEM medium supplemented with D-glucose at a
5.5 mmol/l of concentration, 10% calf serum and 2 mmol/l L-glutamine,
100 units/ml penicillin G sodium and 100 mg/ml streptomycin sulphate for
5 days at NG, HG and ARI+HG conditions.2.1.2. Extraction of nuclear protein and cytoplasmic proteins
Cells were collected and re-suspended in 100 μl of buffer A (10 μmol/l,
HEPES, pH 7.9, 1.5 mmol/l MgCl2, 0.5 mmol/l dithiothreitol (DTT), 0.2% NP-
40, 100 mmol/l 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), 18.4 mg/
ml sodium orthovanadate, 42 mg/ml sodium fluoride and 2.2 mg/ml aprotonin)
and held on ice for 15 min. The resulting cell lysate was then centrifuged at
13,000 rpm for 10 min. The supernatant containing cytoplasmic proteins was
transferred into a fresh tube for Western blotting and the nuclear pellets were re-
suspended in 50 μl of buffer C (20 mmol/l HEPES pH 7.9, 25% glycerol,
0.42 mol/l NaCl, 1.5 mmol/l MgCl2, 0.5 mmol/l DTT, 0.2 mmol/l EDTA,
100 mmol/l AEBSF, 18.4 mg/ml sodium orthovanadate, 42 mg/ml sodium
fluoride, 2.2 mg/ml aprotonin), and incubated on ice for 10 min. After centri-
fugation at 13,000 rpm for 10 min the supernatant containing the nuclear protein
was transferred into a fresh tube and stored at −70 °C until use. The concen-
trations of both nuclear and cytoplasmic proteins were determined using a
Coomassie® Plus Protein Assay kit (Peribo Science Ltd., Chest, UK).
2.1.3. Electrophoretic mobility shift assay (EMSA)
The NFκB probe with consensus sequence to κB motif AAATGGGAAAT-
CACCGGC [7] (Fig. 1A) ofAKR1B1 genewas labelledwith [α-32P] deoxy-ATP
by T4 polynucleotide kinase (Amersham Pharmacia Biotech, Buckinghamshire,
UK). The labelled probe along with a gel binding buffer was incubated with
25 μg of nuclear proteins at room temperature for 20 min. The binding mixtures
were resolved by electrophoresis on a 4% non-denaturing polyacrylamide gel at
100 V for 3 to 4 h. The gel was exposed to X-Omax photographic paper. The
specificity of the DNA-binding protein for the putative binding sites was estab-
lished by specific competitors and antibodies against human NFκB p65 (Insight
Biotechnology Ltd, Wembley, UK), respectively.
2.2. Western blotting
Briefly, a total 50 μg of cytoplasmic proteins was loaded onto a 7.5 or 10%
precast SDS-PAGE (BIO-RAD Laboratory Ltd, Hempstead, UK), electrophor-
esed for 2–3 h at 100 V, and transferred to nitrocellular membrane (Amersham,
USA) overnight. Next, the membrane was blocked with 5% non-fat milk and
0.05% Tween 20–PBS for 1 h at room temperature. Immunoblotting was per-
formed with primary rabbit antibodies against human AKR1B1 and IκB-α
(Abcam Ltd, Cambridge, UK) as well as with primary mouse antibodies against
NFκB p65, phosphorylated IκB-α (Insight Biotechnology Ltd,Wembley, UK) in
appropriate dilutions, respectively. Secondary antibodies against rabbit or mouse
IgG of horse-radish peroxidase-conjugated were used in a 1:10,000 dilution
(Sigma, UK). A chemiluminescence kit (Pierce, UK) and Kodak X-Omat film
(Amersham, UK) were used to detect the amount of proteins. Meantime, in order
to have an equal amount of proteins in all wells, β-actin levels were measured by
using a mouse antibody against human β-actin in 1:10,000 dilution (Sigma, UK)
and a secondary antibody against mouse IgG of horse-radish peroxidase-con-
jugated in 1:10,000 dilution (Sigma, UK).
Fig. 1. A: A sequence scheme of the promoter region of AKR1B1 gene. (AC)n is the dinucleotide repeats located at −2100 and (C/T) is a single nucleotide
polymorphism located at −106 of the gene. OREC is underlined and κB motif is aligned above the OREC. B: DNA-binding activities of NFκB to κB motif in HEK
293 cells, which were cultured under normal conditions. Reactions were incubated with 25 μg of nuclear proteins and labelled NFκB probe without competitor (lane 1:
no protein) and lane 2, or with 50 times competitors corresponding to unlabelled probes OREC (lane 3), NFκB (Lane 4), a mutated probe which is 5-bp mutation of
NFκB probe (lane 5) and AP1 (lane 6). Lane 7 is a supershift assay with a poly-rabbit antibody against human NFκB p65. C: Representative image of DNA binding of
NFκB in nephropath and uncomplicated subjects. The PBMCs were incubated under normal (NG), high glucose (HG: D-glucose at 25 mmol/l) or aldose reductase
inhibitor (ARI: sorbinil at 10 μmol/l) with HG conditions, respectively.
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phosphorylated IκB-α and IκB-α were analysed and quantified by using a
phosphoimager (BIO-RAD, UK) with multi-analyst software. All results were
expressed as means of fold increases due to high glucose treatment, calculated
by dividing the amount of density in high glucose-treated cells by the amount of
density in untreated cells or as means of fold decreases due to ARI treatment,
calculated by dividing the amount of density in high glucose with ARI treated
cells by the amount of density in high glucose-treated cells.
2.3. SiRNA assay
In order to investigate effects of NFκB on the transcription of AKR1B1 gene
under high glucose conditions, we silenced the NFκB gene by RNA inter-
ference. Three siRNA duplex sequences were pre-designed from Ambion
(Ambion Limited, UK), targeting to exons 7, 8 and 9 of the NFκB p65 gene,
respectively. A negative control siRNA was purchased from Ambion as well.
Transfection of siRNAwas carried out by using siFECT siRNA transfection
reagent (Promega, Southampton, UK) and transfection of plasmids was per-formed by using Tfx-20 reagent (Promega, Southampton UK). The day before
transfection, HEK 293 cells (which express NFκB p65 identified by RT-PCR,
data not shown) were seeded at 30% to 50% confluence in 96-well plates and
each transfection was performed in duplicates. siRNA at a concentration range
from 10 nmol/l to 1000 nmol/l was tested and a 500 nmol/l of siRNA gave a
detectable silencing effect. Among three siRNAs, the one targeting exon 9 gave
the highest silencing. Therefore, siRNA targeting at exon 9 and negative control
at a 500 nmol/l were used in our study. For analysing the effect of silencing of
NFκB p65 on the transcription of AKR1B1 gene, recombinant pGL3 reporter
plasmids at 98 ng which contain the promoter region with OREC/κB motif and
haplotypes Z-2/C-106 or Z/C-106 of the AKR1B1 gene [6,18] and firefly
luciferase gene downstream were co-transfected with pRL-TK control plasmids
which contain the Renilla reniformis luciferase gene into the cells at 2 ng after
24 h of siRNA transfection. Next day, cells were divided into four groups: (a)
cells were maintained in original media; (b) cells were switched to HG (a final
concentration at 25 mmol/l of D-glucose); (c) cells were switched to ARI
(sorbinil at 10 μmol/l); and (d) cells were switched to HG and ARI conditions
(ARI was added 3 h earlier before D-glucose was added). All cells were cultured
for another 30 h. At the end of culture, cells were lysed using 20 μl of lysis buffer
Table 1
Clinical characteristics of patients with type 1 diabetes
Nephropaths
(n=20)
Uncomplicated
(n=14)
Male:female 6:14 4:10
Age (years) 49.6±13.9 (30–82) 48.1±14.9 (19–74)
Age at onset of diabetes (years) 12.3±8.8 (1–35) 15.2±9.4) (2–38)
Duration of diabetes (years) 34.9±8.1 (21–49) 34.3±9.4) (20–53)
Plasma Glucose (mmol/l) 9.8±0.8 10.1±1.5
HbA1c (%) 8.2±0.3 8.3±0.3
Data are means±SE (ranges) in years. Levels of plasma and Hemoglobin A1c
(HbA1c) are expressed as means+SE in mmol/l and %, respectively.
Uncomplicated: patients have been diagnosed with type 1 for at least 20 years
but remain free of retinopathy (fewer than five dots or blots per fundus),
proteinuria (urine Albustix negative on at least three consecutive occasions over
12 months) and neuropathy (overt neuropathy was defined if there was any
clinical evidence of peripheral or autonomic neuropathy).
Diabetic nephropaths: patients have had type 1 for at least 8 years with persistent
proteinuria (urine Albustix positive on at least three consecutive occasions over
12 months or three consecutive total urinary protein excretion ratesN0.5 g/24 h)
in the absence of hematuria or infection on midstream urine samples.
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using a Dual-luciferase reporter assay system (Promega, Southampton, UK) in a
MLX luminometer (Dynex Technologies Inc., USA). For each transfection, the
relative activity was defined as firefly luciferase activity normalised by the
activity of the internal control (Renilla luciferase) as described previously [6,18].
2.4. Statistical analysis
All data were expressed as the means±standard error of the means (SE).
Student t-test was used to compare differences between two groups and
ANOVAwas used to compare differences between more than two groups. A p
value of less than 0.05 was considered to be significant.
3. Results
Clinical characteristics of patients with type 1 diabetes with
or without nephropathy are shown in Table 1. There were no
differences in age, gender, age at onset of diabetes, duration of
diabetes, Hb1Ac and glucose levels between two groups.Table 2
DNA-binding activities of NFκB to κB motif in PBMCs under HG and ARI+
HG conditions
NFκB
HG/NG ARI+HG/HG
Nephropaths (n=20) 1.77±0.22a,b 0.58±0.06c
Uncomplicated (n=14) 1.16±0.04d 0.79±0.06
Data are expressed as means of fold increases±SE under high glucose con-
ditions compared to normal conditions (HG/NG) or under the aldose reductase
inhibitor plus high glucose conditions compared to high glucose conditions
without the aldose reductase inhibitor (ARI+HG/HG) in peripheral blood
mononuclear cells (PBMCs). The density value was defined as 1 under normal
conditions (NG: D-glucose at a final concentration of 5.5 mmol/l). High glucose
conditions (HG) are D-glucose at a final concentration of 25 mmol/l and aldose
reductase inhibitor conditions (ARI) are sorbinil at a final concentration of
10 μmol/l.
aversus the uncomplicated under HG conditions ( p=0.02).
bversus the nephropaths under ARI+HG conditions ( p=0.0001).
cversus the uncomplicated under ARI+HG conditions ( p=0.032).
dversus the uncomplicated under ARI+HG conditions ( p=0.0002).3.1. High glucose significantly increased NFκB binding
activities to the κB motif site in PBMCs
We observed that two binding bands were formed in the gel
shit with NFκB probe, which were consistent with Ramana
et al.'s study [15]. In the presence of cold (unlabelled) NFκB
probe, the band was abolished (Fig. 1B). The super shift analysis
of NFκB showed that following the incubation with antibodies
against humanNFκB p65, the binding complexwith the probe to
κB motif was shifted upwards as indicated in Fig. 1B.
The DNA-binding activities of NFκB to the κB motif in
PBMCs exposed to either normal glucose, high glucose or, ARI
with high glucose conditions, from a nephropath and an un-
complicated subject are shown in Fig. 1C. Following the incu-
bation with high glucose there were significantly increased
DNA-binding activities of NFκB to κB motif in PBMCs in both
the nephropaths and uncomplicated subjects. These increases
were particularly significant in the nephropaths compared with
uncomplicated group (1.77±0.22 vs. 1.16±0.04, p=0.02)
(Table 2). ARI treatment significantly decreased the DNA-
binding activities of NFκB to κB motif under high glucose con-
ditions in both the nephropaths by 67% (1.77±0.22 vs. 0.58±
0.06, p=0.0001) and uncomplicated by 32% (1.16±0.04 vs.
0.79±0.06, p=0.0002) groups, respectively (Table 2). The
ARI-linked decrease in NFκB binding activity was signifi-
cantly greater in the nephropaths compared to the uncompli-
cated (0.58±0.06 vs. 0.79±0.06, p=0.032) (Table 2).Fig. 2. Western blotting results with antibodies against human AKR1B1, NFκB
p65, phosphorylated IκB, IκB and β-actin, respectively. Peripheral blood mo-
nonuclear cells (PBMCs) from the nephropaths and uncomplicated subjects
were cultured in normal (NG), high glucose (HG: D-glucose at 25 mmol/l) or
ARI (sorbinil at 10 μmol/l) with HG conditions, respectively.
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AKR1B1
Western blots were used to measure the AKR1B1, NFκB
p65, IκB-α and phosphorylated IκB-α protein levels (Fig. 2). In
the presence of high glucose there was a significant increase in
AKR1B1 protein in PBMCs from the nephropaths compared to
the uncomplicated (1.26±0.08 vs. 0.93±0.07, p=0.02). This is
consistent with our earlier study of elevated AKR1B1 mRNA
and proteins by high glucose in the nephropaths [6,19]. In the
presence of the ARI, the elevation of AKR1B1 protein by high
glucose was significantly suppressed in PBMCs from the ne-
phropaths (1.26±0.08 vs. 0.76±0.07, p=0.01), but not from
uncomplicated subjects (0.93±0.07 vs. 0.81±0.06, p=0.24)
(Table 3). High glucose slightly increased the expression of
NFκB p65 and phosphorylated IκB-α and IκB, respectively, in
PBMC from the nephropaths, but those increases were not
significantly different compared to PBMC from the uncompli-
cated subjects. In the presence of ARI, those protein levels were
decreased by various degrees from 10 to 20% compared with
that under high glucose conditions from the nephropaths, re-
spectively. Again, these changes were not statistically sig-
nificant. All results are summarised in Table 3.
3.3. Silencing of NFκB reduces AKR1B1 gene transcription
These results were consistent with our previous studies
showing [6,18] that the recombinants with the Z-2/C-106
AKR1B1 haplotype had the highest transcriptional activity
among all haplotypes. The Z/C-106 AKR1B1 haplotype had the
second highest transcriptional activity in transfected HEK 293
cells in luciferase assays. High glucose significantly increased
AKR1B1 transcription by 1.2 fold in the HEK 293 cells trans-
fected with both Z-2/C-106 and Z/C-106 AKR1B1 haplotypes,
respectively (Fig. 3A and B). In the presence of the siRNA tar-
getingNFκBp65, transcriptional activities of AKR1B1 in the Z-2/
C-106 recombinants were reduced by 50%, 56%, 60% and 50%
under NG, HG, ARI and ARI with HG, respectively (Fig. 3A).
Similarly, transcriptional activities of AKR1B1 with Z/C-106Table 3
Protein levels of AKR1B1, NFκB and phosphorylated IκB-α and IκB-α in
PBMCs under HG and ARI with HG
Proteins Stress Nephropaths Uncomplicated
AKR1B1 HG/NG 1.26±0.08a,b (n=8) 0.93±0.07 (n=4)
ARI+HG/HG 0.76±0.07 (n=8) 0.81±0.06 (n=4)
NFκB (p65) HG/NG 1.15±0.17 (n=5) 1.06±0.11 (n=3)
ARI+HG/HG 0.75±0.12 (n=5) 0.87±0.07 (n=3)
P-IκB-α HG/NG 1.08±0.15 (n=6) 1.05±0.19 (n=4)
ARI+HG/HG 1.08±0.12 (n=6) 0.92±0.18 (n=4)
IκB-α HG/NG 1.18±0.16 (n=6) 1.15±0.08 (n=5)
ARI+HG/HG 0.88±0.07 (n=6) 0.96±0.05 (n=5)
Data are expressed as means of fold increases±SE under HG (D-glucose at
25 mmol/l) to normal conditions (HG/NG) or under ARI (sorbinil at 10 μmol/l)
with HG conditions to HG conditions (ARI+HG/HG) in peripheral blood
mononuclear cells (PBMCs). Sample sizes are shown within parentheses.
aversus the uncomplicated under HG conditions ( p=0.02).
bversus the nephropaths under ARI+HG conditions ( p=0.01).recombinants were decreased by 50%, 57%, 56% and 37% under
NG, HG, ARI and ARI with HG, respectively (Fig. 3B). The
silencing of NFκB p65 gene was confirmed by Western blotting
by using an antibody against human NFκB p65 (Fig. 3C). How-
ever, the ARI did not decrease transcriptional activities in those
cells transfected with either Z-2/C-106 or Z/C-106 AKR1B1
haplotypes without siRNA transfection. There were no significant
changes in transcriptional activities in transfected cells with the
control siRNA compared to cells without siRNA between either
normal glucose, high glucose or, high glucose and ARI for both
haplotypes (data not shown).
4. Discussion
Chronic hyperglycemia is a major initiator of microvascular
complications in diabetes. Accelerated flux through the polyol
pathway may be a key to the development of diabetic nephro-
pathy and other complications [3]. There is strong evidence that
those patients with diabetic nephropathy have increased expres-
sion and activity of AKR1B1. We previously demonstrated that
the increased expression of AKR1B1 gene is accompanied by
elevated AKR1B1 protein level, is ORE-dependent, and regu-
lated by NFAT5 under high glucose conditions [6]. High glu-
cose induced NFAT5 binding activities to the OREs have been
also observed in the myo-inositol oxygenase (MIOX) gene
[20,21], which is closely linked to the polyol pathway and has
been suggested to play an important role in the development of
diabetic nephropathy [22].
NFκB is activated by a large variety of stimuli including
cytokines, viruses, oxidative stress and genotoxic drugs. There is
growing evidence that high glucose as well as diabetes can
activate NFκB expression [14,23–25]. Previous studies have
shown that NFκB–DNA-binding activity was increased in re-
sponse to elevated glucose in cultured porcine vascular smooth
muscle cells [23] and PBMCs from patients with type 1 diabetes
[14] and the activity correlated with blood glucose levels. In the
present study, we demonstrated that the binding activity of NFκB
to the κB motif of the AKR1B1 gene was significantly increased
under high glucose conditions in nephropaths. In contrast, there
was no increase in NFκB–DNA-binding activity in patients
without microvascular complications. The exact mechanisms
have still to be elucidated and explored, but genetic factors or an
imbalance of redox probably makes important contributions. Our
previous report [26] indicated that there was a defect of anti-
oxidant gene expression in patients with nephropathy. Since high
glucose causes excess free radical generation [27,28], this implies
that the increase in NFκB binding activity may be due to a
generalized response to oxidative stress. This is supported by our
previous report that PBMCs of nephropaths have decreased
expression of cytoplasmic anti-oxidant genes in response to
excess glucose, whilst those from patients with no complications
have a marked increase in expression of these genes [26]. Since
NFκB activation is redox dependent [29,30], and increased
metabolic flux through AKR1B1 is strongly linked to a change in
redox potential within the cell [31], it is possible that NFκB could
provide positive feedback to regulate the level of AKR1B1
expression through κB motif. This notion is supported by our
Fig. 3. Data are means+SE (5 experiments were performed). Results are relative luciferase activity normalised by the activity of the internal control. We defined the
transcriptional activity of Z-2/C-106 haplotype under normal conditions (NG) as 100%. All other values were calculated against it. Duplicated wells were performed
for each transfection. Transfected cells were cultured under NG, HG (D-glucose at 25 mmol/l), ARI (sorbinil at 10 μmol/l) and ARI with HG conditions, respectively
(see Materials and methods). A: Cells were co-transfected with plasmids (promoter of AKR1B1 Z-2/C-106 haplotype) and siRNA targeting to NFκB p65 exon 9. B:
Cells were co-transfected with plasmids (promoter of AKR1B1 Z/C-106 haplotype) and siRNA targeting to NFκB p65 exon 9. ⁎, #, § and ¶ indicate significant
differences of the transcriptional activity between cells transfected with and without siRNA under NG, HG, ARI and ARI+HG conditions for both A and B
( pb0.005), respectively. // indicates that HG significantly increased AKR1B1 transcriptional activity in cells transfected with either Z-2/C-106 or Z/C-106 haplotype,
respectively ( pb0.05). C: Representative Western blotting results (n=4) with antibody against NFκB p65 and β-actin in transfected cells. Lane 1: cells were co-
transfected with negative control siRNA and plasmids (Z-2/C-106); Lane 2 (NG) and 4 (HG): cells were co-transfected with siRNA targeting NFκB p65 exon 9 and
plasmids (Z-2/C-106); Lane 3 (NG) and 5 (HG): cells were transfected with plasmids (Z-2/C-106), but without siRNA.
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both the nephropaths and uncomplicated subjects. It is also
supported by Ramana et al.'s study [15] that ablation of AKR1B1
by siRNA prevented high glucose induced NFκB activation in
vitro. Furthermore, silencing of NFκB p65 significantly de-
creased the transcriptional activity of AKR1B1 in vitro in this
study, which provided solid evidence that high glucose regulatesthe expression ofAKR1B1 gene through the transcriptional factor
NFκB. The susceptible haplotype (Z-2/C-106) to the diabetic
nephropathy showed the highest transcriptional activity and the
common haplotype (Z/C-106) in population showed the second
higher transcriptional activity in luciferase assays, which are
consistent with our previous results [6,18]. The different haplo-
types may change the binding activity of NFκB p65 to the κB
301B. Yang et al. / Biochimica et Biophysica Acta 1782 (2008) 295–302motif in the promoter region of theAKR1B1 gene aswe have seen
in nephropaths. Taken together, reduced luciferase activities by
silencing of both NFAT5 [6] and NFκB p65 expressions in HEK
293 cells transfected with those recombinants support the notion
that interaction between NFAT5 and NFκB is required for
transcription of AKR1B1 gene although we believe that there are
more accessory proteins involved in the binding complex because
our supershift analysis could not completely abolish the bands by
using antibodies against NFκB and NFAT5 (data not shown).
We have demonstrated that increases in NFκB binding
activities in response to high glucose were prevented by treat-
ment with an ARI in PBMCs, particularly in the nephropaths.
These findings together with those reported in cell lines and
other species [32–34] strongly suggest that increased expres-
sion and activity of AKR1B1 are intricately linked with the
activation of the pro-inflammatory transcription factor NFκB.
The precise mechanism underlying these observations has still
to be determined. Recently it has been shown that inhibition of
aldose reductase either by ARIs or SiRNA can abolish many of
the pro-inflammatory effects of NFκB in animal models of
systemic inflammation. The inhibition of aldose reductase can
modify a number of NFκB related molecular and cellular path-
ways within the cell including mitogenic signalling and the
accumulation of products of lipid peroxidation [15,27,35]. A
recent study from the same group showed that high glucose
induced NFκB activation could be prevented by ARI through
inhibition of TNF-α synthesis and secretion in vascular smooth
muscle cell [36]. All those results indicate that ARI could be
modulating the response by decreasing the action of AKR1B1
through its action as a pro-inflammatory mediator [32].
The absence of any significant detectable changes in protein
levels of cytoplasmic NFκB, IkB-α and P-IkB-α in the patient
groups may be due to a number of reasons including higher
DNA-binding affinity of NFκB in the diabetic nephropaths
compared with diabetic controls. This might be influenced by
genetic variation in the promoter region [18]. In addition, pre-
vious reports suggest that the reservoir of individual nuclear
proteins is far greater than the total amount of NFκB protein
actually required for binding to the DNA-binding motifs [37].
Finally, it is likely that access to these motifs differs between
patients with or without nephropathy [18,38]. Consequently, in
our study there may be reduced requirement for NFκB to
translocate from the cytoplasm to the nucleus.
We cannot fully explain patterns of phosphorylated IκB-α and
IκB-α protein levels under various conditions in both groups.
Theoretically, an increase in phosphorylated IκB should be ac-
companied by a decrease in total IκB due to phosphorylation. A
recent review [39] suggested that there are three major NFκB
activating pathways responding to various stimuli: the canonical,
the alternative and atypical pathways. Oxidative stress may lead
to the atypical pathway with a weak and slow NFκB signal (with
peak activities reached after 2–4 h) [40] and long-term high
glucose may generate oxidative and genotoxic stresses, which
may partly induce NFκB activities in an IKK-independent way.
Therefore, the absence of significant decreases in IκB-α ex-
pression in PBMCs may reflect this fact, especially with cells
exposed to chronic high glucose. Our observation is consistentwith previous reports showing sustained NFκB activation in the
absence of significant decreases in IκB-α expression in PBMCs
exposed to chronic high glucose [14].
In conclusion, the exposure of human PBMCs to high glu-
cose in vitro caused increased binding of NFκB to the κB motif.
These increases were significantly higher in patients with the
nephropathy compared to the uncomplicated subjects and were
accompanied with an increase in protein level of AKR1B1. ARI
decreased the binding activity of NFκB to the κB motif in
PBMCs and the effect was greater in PBMC from nephropaths
compared to the uncomplicated subjects. Silencing of NFκB
p65 decreased AKR1B1 transcription in transfected cells, which
indicates that the polyol pathway is partly up-regulated through
NFκB under high glucose conditions.
References
[1] M. Brownlee, The pathobiology of diabetic complications: a unifying
mechanism, Diabetes 54 (2005) 1615–1625.
[2] S.H. Hansen, The role of taurine in diabetes and the development of
diabetic complications, Diabetes Metab. Res. Rev. 17 (2001) 330–346.
[3] Q. Dan, R.L.Wong, S. Yin, S.K. Chung, S.S. Chung, K.S. Lam, Interaction
between the polyol pathway and non-enzymatic glycation onmesangial cell
gene expression, Nephron Exp. Nephrol. 98 (2004) e89–e99.
[4] F.L. Smardo, M.B. Burg, A. Garcia-Perez, Kidney aldose reductase gene
transcription is osmotically regulated, Am. J. Physiol. 262 (1992)C776–C782.
[5] B.C. Ko, B. Ruepp, K.M. Bohren, K.H. Gabbay, S.S. Chung, Identification
and characterisation of multiple osmotic response sequences in the human
aldose reductase gene, J. Biol. Chem. 272 (1997) 16431–16437.
[6] B. Yang, A.D. Hodgkinson, P. Oates, H.M. Kwon, B.A. Millward, A.G.
Demaine, Elevated activity of transcription factor nuclear factor of activated
T-cells 5 (NFAT5) and diabetic nephropathy, Diabetes 55 (2006) 1450–1455.
[7] T. Iwata, S. Sato, J. Jimenez, M. McGowan, M. Moroni, A. Dey, N.
Ibaraki, V.N. Reddy, D. Carper, Osmotic response element is regulated for
the induction of aldose reductase by tumor necrosis factor-α, J. Bio. Chem.
274 (1999) 7993–8001.
[8] B.H. Rovin, J.A. Dickerson, L.C. Tan, C.A. Hebert, Activation of nuclear
factor κB correlates with MCP-1 expression by human mesangial cells,
Kidney Int. 48 (1995) 1263–1271.
[9] N. Abdel Wahab, R.M. Mason, Modulation of neutral protease expression in
human mesangial cells by hyperglycaemic culture, Biochem. J. 320 (1996)
777–783.
[10] P.R. Maxwell, P.M. Timms, S. Chandrant, D. Gordon, Peripheral blood
level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1
diabetes, Diabetes Med. 18 (2001) 777–780.
[11] A.K. Mohamed, A. Bierhaus, S. Schiekofer, H. Trischler, R. Ziegler, P.P.
Narworth, The role of oxidative stress and NF-kappa B activation in late
diabetic complications, Biofactors 10 (1999) 157–167.
[12] M.A. Hofmann, S. Schiekofer, M. Kanitz, M.S. Klevesath, M. Joswig, V.
Lee, M. Morcos, H. Tritschler, R. Ziegler, P. Wahl, A. Bierhaus, P.P.
Nawroth, Insufficient glycaemic control increases nuclear factor-κB bind-
ing activity in peripheral blood mononuclear cells isolated from patients
with type 1 diabetes, Diabetes Care 21 (1998) 1310–1316.
[13] M.A. Hofmann, S. Schiekofer, B. Isermann, M. Kanitz, M. Henkels, M.
Joswig, A. Treusch, M. Morcos, T. Weiss, V. Borcea, A.K. Abdel Khalek,
J. Amiral, H. Tritschler, E. Ritz, P. Wahl, R. Ziegler, A. Bierhaus, P.P.
Nawroth, Peripheral blood mononuclear cells isolated from patients with
diabetic nephropathy show increased activation of the oxidative-stress
sensitive transcription factor NF-κB, Diabetologia 42 (1999) 222–232.
[14] A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P.M. Humpert, J.
Chen, M. Hong, T. Luther, T. Henle, I. Kloting, M. Morcos, M. Hofmann, H.
Tritschler, B. Weigle, M. Kasper, M. Smith, G. Perry, A.M. Schmidt, D.M.
Stern, H.U. Haring, E. Schleicher, P.P. Nawroth, Diabetes-associated sus-
tained activation of the transcription factor nuclear factor-κB, Diabetes 50
(2001) 2792–2808.
302 B. Yang et al. / Biochimica et Biophysica Acta 1782 (2008) 295–302[15] K.V. Ramana, B. Friedrich, S. Srivastava, A. Bhatnagan, S.K. Srivastava,
Activation of nuclear factor-κB by hyperglycemia in vascular smooth muscle
cells is regulated by aldose reductase, Diabetes 53 (2004) 2910–2920.
[16] The Expert Committee on the diagnosis and classification of diabetes
mellitus, Report of the Expert Committee on the diagnosis and classi-
fication of diabetes mellitus, Diabetes Care 26 (2003) S5–S20.
[17] A.E. Heesom, M.L. Hibberd, B.A. Millward, A.G. Demaine, Polymorph-
ism in the 5′-end of the aldose reductase gene is strongly associated with
the development of diabetic nephropathy in type 1 diabetes, Diabetes 46
(1997) 287–291.
[18] B. Yang, A. Millward, A. Demaine, Functional differences between the
susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region poly-
morphisms of the aldose reductase gene may account for the association with
diabetic microvascular complications, Biochem. Biophys. Acta 1639 (2003)
1–7.
[19] A.D. Hodgkinson, K.L. Sondergaard, B. Yang, D.F. Cross, B.A. Millward,
A.G. Demaine, Aldose reductase expression is induced by hyperglycemia
in diabetic nephropathy, Kidney Int. 60 (2001) 211–218.
[20] B. Nayak, P. Xie, S. Akagi, Q. Yang, L. Sun, J. Wada, A. Thakur, F.R.
Danesh, S.S. Chugh, Y.S. Kanwar, Modulation of renal-specific oxido-
reductase myo-inositol oxygenase by high-glucose ambience, Proc. Natl.
Acad. Sci. U. S. A. 102 (2005) 17952–17957.
[21] K.S. Prabhu, R.J. Arner, H. Vunta, C.C. Reddy, Up-regulation of human
myo-inositol oxygenase by hyperosmotic stress in renal proximal tubular
epithelial cells, J. Biol. Chem. 280 (2005) 19895–19901.
[22] R.J. Arner, S. Prabhu, V. Krishnan, M.C. Johnson, C.C. Reddy, Expression
of myo-inositol oxygenase in tissues susceptible to diabetic complications,
Biochem. Biophys. Res. Commun. 339 (2006) 816–820.
[23] K.K. Yerneni, W. Bai, B.V. Khan, R.M. Medford, R. Natarjan, Hyper-
glycaemia induced activation of nuclear transcription factor k B in vascular
smooth muscle cells, Diabetes 48 (1999) 855–864.
[24] C. Guijarro, J. Egido, Transcription factor-kB (NFkB) and renal disease,
Kidney Int. 59 (2001) 415–424.
[25] Y. Hattori, S. Hattori, N. Sato, K. Kasai, High-glucose-induced nuclear
factor κB activation in vascular smooth muscle cells, Cardiovasc. Res. 46
(2000) 188–197.
[26] A.D. Hodgkinson, T. Bartlett, P.J. Oates, B.A. Millward, A.G. Demaine, The
response of antioxidant genes to hyperglycemia is abnormal in patients with
type 1 diabetes and diabetic nephropathy, Diabetes 52 (2003) 846–851.[27] I.G. Obrosova, How does glucose generate oxidative stress in peripheral
nerve? Int. Rev. Neurobiol. 50 (2002) 3–35.
[28] S. Gupta, E. Chough, J. Daley, P. Oates, K. Tornheim, N.B. Ruderman, J.F.
Keaney Jr., Hyperglycemia increases endothelial superoxide that impairs
smooth muscle cell Na+-K+-ATPase activity, Am. J. Physiol. Cell. Physiol.
282 (2002) C560–C566.
[29] P.A. Baeuerle, D. Baltimore, NF-κB: ten years after, Cell 87 (1996)
1066–1071.
[30] P.J. Barnes, M. Karin, Nuclear factor-κB a pivotal transcription factor in
chronic inflammatory diseases, New Engl. J. Med. 336 (1997) 1066–1071.
[31] S.S.M. Chung, E.C.M. Ho, K.SL. Lam, S.K. Chung, Contribution of
polyol pathway to diabetes-induced oxidative stress, J. Am. Soc. Nephrol.
14 (2003) S233–S236.
[32] K.V. Ramana, B. Friedrich, A. Bhatnagar, S.K. Srivastava, Aldose reduc-
tase mediates cytotoxic signals of hyperglycaemia and TNF-α in human
lens epithelial cells, FASEB J. 17 (2003) 315–317.
[33] J.R. Williamson, K. Chang, M. Frangos, K.S. Hasan, Y. Ido, T. Kawamura,
J.R. Nyengaard, M. van den Enden, C. Kilo, R.G. Tilton, Hyperglycemic
pseudohypoxia and diabetic complications, Diabetes 42 (1993) 801–813.
[34] K.V. Ramana, D. Chandra, S. Srivastava, A. Bhatnagar, B.B. Aggarwal, S.
K. Srivastava, Aldose reductase mediates mitogenic signalling in vascular
smooth muscle cells, J. Biol. Chem. 277 (2002) 32063–32070.
[35] K.V. Ramana, M.S. Willis, M.D. White, J.W. Horton, J.M. DiMaio, D.
Strivastava, A. Bhatnagar, S.K. Srivastava, Endotoxin-induced cardio-
myopathy and systemic inflammation in mice is prevented by aldose
reductase inhibition, Circulation 114 (2006) 1838–1846.
[36] K.V. Ramana, R. Tammaki, A.B. Reddy, A. Bhatnagar, S.K. Srivastava,
Aldose reductase-regulated tumour necrosis factor-alpha production is
essential for high glucose-induced vascular smooth muscle cell growth,
Endocrinology 148 (2007) 4371–4384.
[37] G. Natoli, S. Saccani, D. Bosisio, I. Marazzi, Interaction of NF-κB with
chromatin: the art of being at the right place at the right time, Nat. Immunol.
6 (2005) 439–445.
[38] S. Saccani, S. Pantano, G. Natoli, Two waves of nuclear factor κB recruit-
ment to target promoters, J. Exp. Med. 193 (2001) 1351–1359.
[39] S. Janssens, J. Tschopp, Signals from within: the DNA-damage-induced
NFκB response, Cell Death Differ. 13 (2006) 773–784.
[40] N. Li, M. Karin, Is NFκB the sensor of oxidative stress? FASEB J. 13
(1999) 1137–1143.
